Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
Links relacionados
- Similares em SciELO
Compartilhar
Revista de la Facultad de Medicina Humana
versão impressa ISSN 1814-5469versão On-line ISSN 2308-0531
Resumo
MEJIA-CABRERA, Selene C. et al. Response to Temozolomide in patients with metastatic melanoma in a third level medical facility. Rev. Fac. Med. Hum. [online]. 2022, vol.22, n.2, pp.252-257. Epub 16-Mar-2022. ISSN 1814-5469. http://dx.doi.org/10.25176/rfmh.v22i2.4788.
Introduction:
Melanoma is a public health problem, it represents 4% of malignant skin tumors and is responsible for 80% of deaths from this type of neoplasm.
Objective
: To present the response to Temozolomide in patients with metastatic melanoma.
Methods:
Descriptive and cross-sectional study. The clinical response of patients with metastatic melanoma, managed with Temozolomide 200 mg/m2 once a day, for five days every 28 days, was analyzed. The risk factors analyzed were: histological variety, topographic region of the primary lesion, metastasis, ulceration and Breslow. Descriptive statistics were used, for normality Kolmogorov-Smirnoff, Student's t-test, as well as binary logistic regression.
Results:
There were 51 files, 47 met the criteria; 25 men, 22 women, mean age 54.5, minimum 22, maximum 85 years. Complete response was obtained in 3(6%), partial response in 7(14.8%), stable disease in 10(21%) and disease progression in 27(57.4%) patients. The presence of ulceration is associated with a higher Breslow index, and as a result, a higher risk of disease progression.
Conclusions:
Temozolomide as monotherapy is a treatment that presents low rates of complete response and partial response, showing better results in patients with lymph node metastases.
Palavras-chave : Malignant melanoma; Metastasis; Temozolomide. (fuente: MeSH NLM)..